)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (ARWR) investor relations material
Arrowhead Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Financial overview and resources
Market cap is approximately $9 billion with 136 million shares outstanding and a stock price of $6.456.
Cash and investments total about $920 million, not including $200 million invoiced from Sarepta, $200 million received from Novartis, and $930 million from recent offerings.
Additional $50 million expected from Sarepta in early 2026, providing ample capital for pipeline advancement.
No immediate plans to partner key obesity assets due to strong cash position.
Independent launches planned for major pipeline drugs in the US.
Pipeline and platform highlights
First commercial launch with Rudemplo, approved in the US, Canada, and China for FCS, with plans for label expansion.
Pipeline includes 20 clinical-stage programs: 11 wholly owned, 9 partnered, spanning rare and prevalent diseases.
Proprietary TRiM platform enables RNAi delivery to seven cell types, with new cell types targeted every 18 months.
Focus on cardiometabolic, obesity, and CNS indications, with multiple late-stage and early-stage candidates.
Dimers and combination therapies are a strategic focus for future pipeline growth.
Key program updates and clinical milestones
Rudemplo showed ~80% triglyceride reduction in FCS, with 75% of patients below 880 mg/dL and 50% below 500 mg/dL.
Phase 3 studies for SHTG label expansion expected to read out in Q3 2026, with sNDA filing in Q4 2026 and launch in 2027.
Zodasiran demonstrated 41% LDL-C reduction in HoFH, 62% with PCSK9 background; phase 3 enrollment ongoing, targeting 2028 launch.
ARO-Dimer-PA, a dual PCSK9/ApoC3 silencer, entering phase 1/2 in mixed hyperlipidemia; initial data expected end of Q3.
Obesity candidates ARO-INHBE and ARO-ALK7 showed promising early data, with combination therapy doubling weight loss versus tirzepatide alone.
Explain obesity program partnering strategy.
ARO-MAPT data's impact on CNS platform validation.
Detail ARO-DIMER-PA's near-term regulatory path.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arrowhead Pharmaceuticals earnings date
Q1 20269 Feb, 2026
Arrowhead Pharmaceuticals
Next Arrowhead Pharmaceuticals earnings date
Q1 20269 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Arrowhead Pharmaceuticals Inc develops therapies that leverage RNA interference (RNAi) to treat genetic diseases. Its pipeline targets conditions in areas such as liver disease, cardiovascular disease, and oncology. The company is headquartered in Pasadena, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage